DE602007013213D1 - Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung - Google Patents

Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung

Info

Publication number
DE602007013213D1
DE602007013213D1 DE602007013213T DE602007013213T DE602007013213D1 DE 602007013213 D1 DE602007013213 D1 DE 602007013213D1 DE 602007013213 T DE602007013213 T DE 602007013213T DE 602007013213 T DE602007013213 T DE 602007013213T DE 602007013213 D1 DE602007013213 D1 DE 602007013213D1
Authority
DE
Germany
Prior art keywords
lxr
sirt1
complex
cholesterol
cholesteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013213T
Other languages
English (en)
Inventor
Leonard Guarente
Monty Krieger
Xiaoling Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of DE602007013213D1 publication Critical patent/DE602007013213D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602007013213T 2006-06-06 2007-06-06 Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung Active DE602007013213D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81115406P 2006-06-06 2006-06-06
PCT/US2007/013364 WO2007146023A1 (en) 2006-06-06 2007-06-06 Cholesterol-regulating complex of sirt1 and lxr and methods of use

Publications (1)

Publication Number Publication Date
DE602007013213D1 true DE602007013213D1 (de) 2011-04-28

Family

ID=38832070

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007013213T Active DE602007013213D1 (de) 2006-06-06 2007-06-06 Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung

Country Status (10)

Country Link
US (1) US20100240029A1 (de)
EP (1) EP2024511B1 (de)
JP (1) JP2009539844A (de)
CN (1) CN101501220A (de)
AT (1) ATE502121T1 (de)
AU (1) AU2007258594A1 (de)
CA (1) CA2654701A1 (de)
DE (1) DE602007013213D1 (de)
ES (1) ES2362941T3 (de)
WO (1) WO2007146023A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
US7572575B2 (en) 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
WO2005002527A2 (en) * 2003-07-03 2005-01-13 Massachusetts Institute Of Technology Sirt1 modulation of adipogenesis and adipose function
US20050164969A1 (en) * 2003-11-19 2005-07-28 Massachusetts Institute Of Technology Method of extending life span
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
CA3128549A1 (en) 2010-07-12 2012-01-19 Universitat Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
CA2857231A1 (en) 2011-12-06 2013-06-13 Unilever Plc Skin anti-ageing composition
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
US20160354489A1 (en) * 2013-09-26 2016-12-08 Universitat Autònome de Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
US10973931B2 (en) 2014-09-16 2021-04-13 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
JP6607735B2 (ja) * 2014-10-16 2019-11-20 シスメックス株式会社 リポタンパク質のコレステロール取り込み能を測定する方法及び試薬キット
ES2900973T3 (es) 2015-01-07 2022-03-21 UNIV AUTòNOMA DE BARCELONA Constructo genético de vector individual que comprende genes de insulina y glucoquinasa
CN108300774A (zh) * 2017-12-01 2018-07-20 苏州睿迈英基因检测科技有限公司 一种改进的开放染色质检测方法及其试剂盒和应用
KR20220016957A (ko) * 2019-06-26 2022-02-10 에프. 호프만-라 로슈 아게 Sirt-1 유전자 녹아웃을 갖는 포유류 세포주

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5506337A (en) * 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5744300A (en) * 1993-03-24 1998-04-28 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes
US5919618A (en) * 1993-08-16 1999-07-06 Massachusetts Institute Of Technology Genes determining cellular senescence in yeast
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) * 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5565323A (en) * 1994-03-30 1996-10-15 Mitokor Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease
US5840493A (en) * 1994-03-30 1998-11-24 Mitokor Mitochondrial DNA mutations that segregate with late onset diabetes mellitus
US6027883A (en) * 1994-03-30 2000-02-22 Mitokor Optimal procedure for isolation of mutant mitochondrial alleles
US5817782A (en) * 1994-06-03 1998-10-06 Research Corporation Technologies, Inc. Lag 1:gene for increasing the longevity of eukaryotes
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5998131A (en) * 1994-10-07 1999-12-07 Lxr Biotechnology, Inc. Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
US6291172B1 (en) * 1995-03-03 2001-09-18 Mitokor Diagnostic assay for diabetes mellitus based on mutational burden
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5705350A (en) * 1995-08-29 1998-01-06 Duke University Transcription factor complexes in senescent cells
US5965543A (en) * 1996-04-18 1999-10-12 Geron Corporation Senescence responsive transcriptional element
JPH109075A (ja) * 1996-06-20 1998-01-13 Hitachi Ltd 燃料供給装置及びこれを用いた内燃機関及び自動車
US6228583B1 (en) * 1997-08-04 2001-05-08 Massachusetts Institute Of Technology Assays for compounds which extend life span
US6835563B1 (en) * 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US7572575B2 (en) * 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
US7241743B2 (en) * 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
AU2003209060A1 (en) * 2002-02-07 2003-09-02 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
US20030228607A1 (en) * 2002-04-15 2003-12-11 Wagner Brandee Lynn Screening method and modulators having an improved therapeutic profile
AU2003249302A1 (en) * 2002-07-17 2004-02-02 Sepro Corporation Herbicide-resistant plants, and polynucleotides and methods for providing same
WO2005002527A2 (en) * 2003-07-03 2005-01-13 Massachusetts Institute Of Technology Sirt1 modulation of adipogenesis and adipose function
US20050164969A1 (en) * 2003-11-19 2005-07-28 Massachusetts Institute Of Technology Method of extending life span
TWI238605B (en) * 2004-07-27 2005-08-21 Quanta Comp Inc Method for transmitting and receiving blue-tooth data and its apparatus
US20070099830A1 (en) * 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities

Also Published As

Publication number Publication date
EP2024511A4 (de) 2010-02-03
ATE502121T1 (de) 2011-04-15
ES2362941T3 (es) 2011-07-15
CA2654701A1 (en) 2007-12-21
US20100240029A1 (en) 2010-09-23
CN101501220A (zh) 2009-08-05
AU2007258594A1 (en) 2007-12-21
EP2024511B1 (de) 2011-03-16
WO2007146023A1 (en) 2007-12-21
EP2024511A1 (de) 2009-02-18
JP2009539844A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
DE602007013213D1 (de) Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung
Pierron et al. Effect of low-dose cadmium exposure on DNA methylation in the endangered European eel
Khew-Goodall et al. Myc-modulated miR-9 makes more metastases
Pavlovic et al. A comparative assessment of human and chimpanzee iPSC-derived cardiomyocytes with primary heart tissues
Oomen et al. Concern-driven integrated approaches to nanomaterial testing and assessment–report of the NanoSafety Cluster Working Group 10
Moro et al. Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol
Weaver Towards sustainable mass tourism: Paradigm shift or paradigm nudge?
ATE552505T1 (de) Quantifizierbare interne referenzstandards für immunhistochemie und verwendung
FR2926375B1 (fr) Procede d'execution d'une application informatique, kit et aeronef associes
Mees Who killed Melbourne 2030?
D’Ambrosio et al. The Metropolis research. Experimental models and decision-making processes for the adaptive environmental design in climate change
RU2012127032A (ru) Способ прогнозирования риска раннего развития атеросклероза у больных хроническим простатитом
Teng et al. The relationship between Lin28 and the chemotherapy response of gastric cancer
Trias-Llimós et al. Smoking cessation among European older adults: the contributions of marital and employment transitions by gender
Caspeele Probabilistic evaluation of conformity control and the use of Bayesian updating techniques in the framework of safety analyses of concrete structures
Aresti Doing time after time a hermeneutic phenomenological understanding of reformed ex-prisoners experiences of self-change and identity negotiation
Yang et al. Does environmental regulation improve public health? Evidence from China's Two Control Zones policy
Ramis-Conde et al. From genotypes to phenotypes: classification of the tumour profiles for different variants of the cadherin adhesion pathway
Safaee et al. Epidemiology and histopathological features of esophageal cancer
Liu et al. Expressions and Significances of CRABPII and E-FABP in Non-small Cell Lung Cancer.
Hu et al. Clinicopathological features and prognostic implications of Raf kinase inhibitor protein downregulation in tongue squamous cell carcinoma
Petherick Environment and genetics: making sense of the noise
WO2012138740A3 (en) Risk analysis for disease development
Elsageer Early age strength development of fly ash mixes as affected by temperature
Basijokaite et al. Time-Varying Sensitivity Analysis and its Relationship to Shifting Annual Conditions in California Watersheds